文章摘要

血清ProGRP在小细胞肺癌诊断和预后中的应用

作者: 1张 兵, 1陈 楠, 1吴 安皓, 1李 恒, 1张 飞越, 1马 千里, 1李 鸣杰, 1张 俊枝, 1李 高峰
1 昆明医科大学第三附属医院,云南省肿瘤医院胸外二科,昆明 650118
通讯: 李 高峰 Email: ligaofenghl@126.com
DOI: 10.3978/j.issn.2095-6959.2020.04.029
基金: 国家自然科学基金(81460356,81760554);2017年国家重点研发项目(2017YFC1308704);云南省科学教育基金(2019J1275)。

摘要

肺癌是全球发病率和病死率最高的恶性肿瘤,其中小细胞肺癌(small cell lung cancer,SCLC)预后最差。血清肿瘤标志物在肺部肿瘤的诊断及预后中的作用越来越受关注,胃泌素释放肽前体(pro-gastrin-releasing peptide,ProGRP)是SCLC分泌的一种具有高度特异性的神经肽,其对诊断SCLC具有灵敏度高和特异度高等优点。血清ProGRP对SCLC的复发、预后评估以及化疗和放疗病程监测中有重要意义。此外,ProGRP在SCLC的发生发展中发挥促癌作用。因此,血清ProGRP有望成为评价SCLC病变进展的可靠指标。
关键词: 胃泌素释放肽前体;小细胞肺癌;诊断;预后

Application of serum pro-gastrin-releasing peptide in diagnosis and prognosis of small cell lung cancer

Authors: 1ZHANG Bing, 1CHEN Nan, 1WU Anhao, 1LI Heng, 1ZHANG Feiyue, 1MA Qianli, 1LI Mingjie, 1ZHANG Junzhi, 1LI Gaofeng
1 Second Department of Thoracic Surgery, Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China

CorrespondingAuthor:LI Gaofeng Email: ligaofenghl@126.com

Foundation: This work was supported by the National Natural Science Foundation (81460356, 81760554), the National Key Research and Development Project in 2017 (2017YFC1308704), and the Research Projects of Yunnan Science Education Fund (2019J1275), China.

Abstract

Lung cancer is the most common malignant tumor with the highest morbidity and mortality rate, and the prognosis of small cell lung cancer is the worst poor. The role of serum tumor markers in the diagnosis and prognosis of lung tumors is of increasing concern. Pro-gastrin-releasing peptide (ProGRP) is highly secreted by small cell lung cancer. Neuropeptide, which has the advantages of high sensitivity and high specificity for the diagnosis of small cell lung cancer. The serum ProGRP is also important for the recurrence, prognosis assessment of small cell lung cancer and monitoring of chemotherapy and radiotherapy. In addition, ProGRP plays a cancer-promoting role in the development of small cell lung cancer. Therefore, serum ProGRP is expected to be a reliable indicator for evaluating the progression of small cell lung cancer.
Keywords: gastrin-releasing peptide precursor; small cell lung cancer; diagnosis; prognosis